文献速递产科麻醉疼痛医学

椎管内无防腐剂吗啡用于阴道分娩对阿片消耗与恢复的影响:一项随机对照试验

Impact of Neuraxial Preservative-Free Morphine in Vaginal Delivery on Opiate Consumption and Recovery: A Randomized Control Trial.
PubMed 文献 · Anesth Analg · 2025-01-01

本研究纳入157例接受硬膜外镇痛的阴道分娩产妇,随机给予硬膜外2 mg无防腐剂吗啡或生理盐水。吗啡组产后24小时内阿片使用率及总剂量更低、24小时疼痛评分更低,但瘙痒发生率更高;两组在恢复质量、母乳喂养成功及产后6周抑郁评分上无差异。

要点

  • 阴道分娩后单次硬膜外2 mg无防腐剂吗啡可减少24小时内阿片使用及疼痛评分。
  • 该方案增加瘙痒发生率,用药组37.5%对比对照组18.2%。
  • 未发现对恢复质量、母乳喂养成功或产后抑郁评分的差异。

核心结论

  • 阴道分娩后单次硬膜外2 mg无防腐剂吗啡可有效降低24小时疼痛及阿片使用,但瘙痒增加。
  • 未检测到母乳喂养、恢复评分或产后抑郁的差异。

研究设计与样本

  • 随机对照试验,纳入157例经阴道分娩并使用硬膜外镇痛的产妇,吗啡组80例,生理盐水组77例。
  • 分娩后1小时内经硬膜外导管给予2 mg无防腐剂吗啡(4 mL)或生理盐水(4 mL)。

主要发现

  • 24小时内阿片使用率:吗啡组3.8%(95%CI 0.9%-11.3%),生理盐水组14.3%(95%CI 7.7%-24.5%)。

临床怎么用

  • 对接受硬膜外镇痛的阴道分娩产妇,可考虑产后单次硬膜外2 mg无防腐剂吗啡以减轻疼痛和阿片需求。
  • 需权衡瘙痒风险,用药后应监测瘙痒并做好处理准备。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuraxial opioids are commonly used after cesarean delivery (CD). However, they are not commonly used after vaginal delivery (VD) though some studies have suggested they may be beneficial from a pain perspective. However, they did not evaluate other potential benefits including patient satisfaction, impact on postpartum depression and breastfeeding (BF) success, or side effects such as pruritus. METHODS: Parturients who delivered vaginally with epidural analgesia were randomized to receive either 2 mg of preservative-free morphine (4 mL) or saline (4 mL) via the epidural catheter within 1 hour of VD. Routine analgesics were unchanged and included q 6-hour dosing of acetaminophen 975 mg orally and ketorolac 30 mg intravenous (IV). Hydromorphone 2 mg or oxycodone 10 mg were offered for breakthrough pain. Our primary outcome was opiate consumption in the first 24 hours after drug administration. Secondary outcomes included pain scores at 24 hours and 1 week postpartum as well as opiate consumption up to 1 week postpartum. Additional end points such as obstetric quality of recovery score (OBS-QOR10) breast feeding success, and an Edinburgh Postnatal Depression Score (EPDS) were also obtained. RESULTS: Data were analyzed for 157 parturients, 80 in the morphine group and 77 in the saline group. No difference was observed in the EDPS score predelivery or intention to BF. We found a statistically significant difference in the use of opioids in the first 24 hours, 3.8% (95% confidence interval [CI], 0.9%-11.3%) vs 14.3% (7.7%-24.5%) in the morphine and saline groups, respectively; and in total opioid dose, median (interquartile range, IQR [range]) of morphine milligram equivalent vs 0 (0-0 [0-47.5]) vs 0 (0-0 [0-72]), P = .023, in the morphine and saline groups, respectively. Verbal pain scores (0-10) at 24 hours were lower in the morphine group (median (IQR [range): 2.0 (1-4 [0-10]) vs 3.0 (1.5-5.0 [0-10]), P = .043. There was a greater incidence of pruritus in the morphine group versus saline group, 37.5% (95% CI, 27.1%-49.1%) vs 18.2% (95% CI, 10.6%-29.0%), P = .008. We did not find any differences in the OBS-QOR10, BF success, or EPDS at 6 weeks PP ( P < .05). CONCLUSIONS: A single epidural dose of 2 mg preservative-free morphine after VD was effective at decreasing pain and opioid use at 24 hours after VD but came at the cost of increased pruritus. We did not detect any differences in BF, recovery scores, or PPD. Future studies should focus on elucidating the role of neuraxial preservative-free morphine after VD.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Katz D, Hyers B, Siddiqui S, et al. Impact of Neuraxial Preservative-Free Morphine in Vaginal Delivery on Opiate Consumption and Recovery: A Randomized Control Trial. Anesth Analg. 2025. PMID: 39028662. doi:10.1213/ANE.0000000000006987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。